Applauds President Trump’s executive order directing the reclassification of cannabis as a less dangerous substance from Schedule I to Schedule III controlled substance while also mentioning the importance of scientific research. Avicanna is also pleased to provide a scientific update on advancements across the Company’s research and development, clinical development, and medical affairs programs. Avicanna Inc. shares T.AVCN are trading down $0.02 at $0.22.
Stocks in play: Avicanna Inc.
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)